Related Experiment Videos

MEF-2 isoforms' (A-D) roles in development and tumorigenesis

Kiran Madugula1, Ria Mulherkar1, Zafar K Khan1

  • 1Department of Microbiology and Immunology, the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19129, USA.

Oncotarget
|May 21, 2019
PubMed

Insights

Myocyte enhancer factor (MEF)-2 isoforms regulate cell development and fate across multiple systems. Dysregulation of MEF-2 transcription factors contributes to diseases like cancer and infection.

Area of Science:

  • Molecular Biology
  • Developmental Biology
  • Genetics

Background:

  • Myocyte enhancer factor (MEF)-2 is crucial for cell proliferation, differentiation, and development.
  • Four MEF-2 isoforms (A-D) exhibit distinct roles in cardiac, muscle, vascular, immune, and skeletal system development.
  • MEF-2 interactions with cellular factors influence protein networks, modulating cell differentiation, proliferation, survival, and apoptosis.

Purpose of the Study:

  • To provide a comprehensive review of MEF-2 isoforms (A-D).
  • To detail MEF-2 localization, signaling pathways, and roles in development and tumorigenesis.
  • To explore the association of MEF-2 with histone deacetylases (HDACs) for therapeutic potential.

Main Methods:

  • Literature review of studies on MEF-2 function and regulation.
  • Analysis of MEF-2 isoform-specific roles in various cell types.
  • Examination of MEF-2 involvement in disease phenotypes and therapeutic targets.

Main Results:

  • MEF-2 isoforms exhibit tissue-specific functions in development.
  • Alterations in MEF-2 transcription factors are linked to diverse disease phenotypes, including cancer and infections.
  • MEF-2 interacts with HDACs, presenting potential therapeutic intervention strategies.

Conclusions:

  • MEF-2 transcription factors are key regulators of cellular processes and development.
  • Aberrant MEF-2 activity contributes to various pathologies.
  • Targeting MEF-2 and its interactions, such as with HDACs, holds promise for therapeutic development.

Related Concept Videos